Slide 1: A First in Class Virus-Like Drug Conjugate Shows Anti-tumor Activity in Cancers that Commonly Metastasize to the Choroid
A First in Class Virus-Like Drug Conjugate (VDC) Shows Anti-tumor Activity in Cancers that Commonly Metastasize to the Choroid Savinainen, Anneli; Kines, Rhonda; Rich, Cadmus Aura Biosciences Cambridge, Massachusetts
Slide 2: Disclosures
Disclosures Anneli Savinainen: Employee at Aura Biosciences Rhonda Kines: Employee at Aura Biosciences Cadmus Rich: Employee at Aura Biosciences 2
Slide 3: Targeted Oncology Platform: Virus-Like Drug Conjugates (VDCs)
Targeted Oncology Platform: Virus-Like Drug Conjugates (VDCs) Virus-Like Particles Covalently Bound VDCs can Recognize Heparin Sulfate Proteoglycans (HSPGs) to a Cytotoxic Payload to form the VDC Specifically Modified by Tumor Cells Cx Virus-Like Particle Virus-Like Drug Cytotoxic Drug (VLP) Conjuga
Slide 4: AU-011 is a VDC with a Novel Dual Mechanism of Action
AU-011 is a VDC with a Novel Dual Mechanism of Action Phthalocyanine dye AU-011 AU-011 is a novel VDC that consists of an HPV derived VLP conjugated to ~200 molecules of Phthalocyanine dye AU-011 Demonstrated Positive Data in Phase 1b/2 Trial in Choroidal Melanoma Kines et al; Cancer Immunology Rese
Slide 5: Choroidal Metastasis – Background
Choroidal Metastasis – Background C-Mets Originates from Multiple Primary Cancers1 Common Unilateral Features of C-Mets3 (72%) Unilateral Solitary (72%) Skin Breast 2% 40-53% Choroidal location (88%) Lung Kidney 20-29% 2% Choroidal Metastasis Prostate GI from non- 2% 4% small cell lung cancer4
Slide 6: AU-011 Induced Potent Cytotoxicity in Multiple Human Cancer Cell Lines Commonly Causing Choroidal Metastasis
AU-011 Induced Potent Cytotoxicity in Multiple Human Cancer Cell Lines Commonly Causing Choroidal Metastasis Skin (2%) Breast (40-53%) EC50 = 5 - 113 pM EC50 = 58 - 118 pM Kidney (2%) Lung (20-29%) EC50 = 21 - 82 pM EC50 = 20 - 40 pM Prostate (2%) EC50 = 13 - 560 pM GI (4%) EC50 = 34 - 386 pM AU-011
Slide 7: AU-011 Demonstrated Binding and Potent Cytotoxicity in Multiple Human Cancer Cell Lines
AU-011 Demonstrated Binding and Potent Cytotoxicity in Multiple Human Cancer Cell Lines Commonly Causing Choroidal Metastasis Breast Colon Renal T47D HT29 RXF-393 100 100 100 AU-011 0J AU-011, 0J AU-011 + heparin 0J/cm2 AU-011 + heparin, 0J AU-011 0J AU-011 + heparin 0J/cm2 AU-011 25J 80 AU-011, 25J
Slide 8: Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival – Breast Cancer
Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival in a Dose-Dependent Fashion – Breast Cancer Breast Cancer In-Vivo (Syngeneic Mouse Model, EMT-6) Reduced Tumor Growth Prolonged Survival Tumor cells were implanted subcutaneously. AU-011 treatment was initiated when tumors
Slide 9: Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival – Renal Cancer
Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival in a Dose-Dependent Fashion – Renal Cancer Renal Cancer In-Vivo (Syngeneic Mouse Model, RENCA) Reduced Tumor Growth Prolonged Survival Tumor cells were implanted subcutaneously. AU-011 treatment was initiated when tumors r
Slide 10: Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival – Colon Cancer
Single Administration of AU-011 Inhibited Tumor Growth and Prolonged Survival in a Dose-Dependent Fashion – Colon Cancer Colon Cancer In-Vivo (Syngeneic Mouse Model, CT26) Reduced Tumor Growth Prolonged Survival Tumor cells were implanted subcutaneously. AU-011 treatment was initiated when tumors re
Slide 11: Conclusion
Conclusion AU-011 can bind to, and kill, tumor cells derived from the most common cancer types known to metastasize to the choroid – Binds to modified HSPG’s on the surface of cancer cells – No cytotoxicity in the absence of light activation AU-011 showed dose-dependent activity in vivo using syngen
Slide 12: Contact Information
Contact Information Anneli Savinainen VP, Head of Preclinical R&D asavinainen@aurabiosciences.com